<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Diffusion Pharmaceuticals &#187; Awards</title>
	<atom:link href="http://www.diffusionpharma.com/category/awards/feed" rel="self" type="application/rss+xml" />
	<link>http://www.diffusionpharma.com</link>
	<description></description>
	<lastBuildDate>Mon, 06 Feb 2012 14:39:17 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1</generator>
		<item>
		<title>Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer</title>
		<link>http://www.diffusionpharma.com/research/fda-grants-orphan-drug-status-for-tsc-in-cancer</link>
		<comments>http://www.diffusionpharma.com/research/fda-grants-orphan-drug-status-for-tsc-in-cancer#comments</comments>
		<pubDate>Tue, 26 Jul 2011 14:32:05 +0000</pubDate>
		<dc:creator>Tracey Danner</dc:creator>
				<category><![CDATA[Awards]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[brain cancer]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Diffusion Pharmaceuticals]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[GBM]]></category>
		<category><![CDATA[glioblastoma multiforme]]></category>
		<category><![CDATA[Orphan Drug Designation]]></category>
		<category><![CDATA[trans sodium croctetinate]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=427</guid>
		<description><![CDATA[Charlottesville, VA – July 26, 2011 – Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company’s lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.  GBM is one of [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/research/fda-grants-orphan-drug-status-for-tsc-in-cancer/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diffusion Pharmaceuticals One of 45 Virginia Companies to Receive Federal Grant</title>
		<link>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-one-of-45-virginia-companies-to-receive-federal-grant</link>
		<comments>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-one-of-45-virginia-companies-to-receive-federal-grant#comments</comments>
		<pubDate>Thu, 04 Nov 2010 19:12:46 +0000</pubDate>
		<dc:creator>Tracey Danner</dc:creator>
				<category><![CDATA[Awards]]></category>
		<category><![CDATA[Funding]]></category>
		<category><![CDATA[Progress]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=338</guid>
		<description><![CDATA[“This non-dilutive award will advance our clinical program and aid us in our mission to introduce approved novel and effective therapies as quickly as possible, providing new hope for patients with PAD, cancer and other conditions related to hypoxia,” said David G. Kalergis, CEO, Diffusion Pharmaceuticals.”
]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-one-of-45-virginia-companies-to-receive-federal-grant/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diffusion Pharmaceuticals Announces Issuance of New U.S. Patent</title>
		<link>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-announces-issuance-of-new-u-s-patent</link>
		<comments>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-announces-issuance-of-new-u-s-patent#comments</comments>
		<pubDate>Mon, 02 Aug 2010 14:00:17 +0000</pubDate>
		<dc:creator>Tracey Danner</dc:creator>
				<category><![CDATA[Awards]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[first-in-class drugs]]></category>
		<category><![CDATA[hypoxia]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[US patent issued]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=251</guid>
		<description><![CDATA[CHARLOTTESVILLE, VA –August 2, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes drug formulation and use claims relating to Diffusion’s entire family of first-in-class new chemical entities. [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/progress/diffusion-pharmaceuticals-announces-issuance-of-new-u-s-patent/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

